On the public citation graph
First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
0 signed · 63 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ajh.24186openalex-snapshot
The impact of dasatinib on pregnancy outcomes
inferredcites →https://doi.org/10.1002/cncr.25648openalex-snapshot
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia
inferredcites →https://doi.org/10.1002/ijc.29889openalex-snapshot
Tyrosine kinase inhibitors as a first‐line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed‐treatment comparison
inferredcites →https://doi.org/10.1007/s00432-018-2604-xopenalex-snapshot
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
inferredcites →https://doi.org/10.1007/s11912-017-0642-1openalex-snapshot
Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia
inferredcites →https://doi.org/10.1016/s2352-3026(16)30167-3openalex-snapshot
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
inferredcites →https://doi.org/10.1038/leu.2016.115openalex-snapshot
The concept of treatment-free remission in chronic myeloid leukemia
inferredcites →https://doi.org/10.1038/leu.2016.5openalex-snapshot
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
inferredcites →https://doi.org/10.1038/leu.2017.63openalex-snapshot
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
inferredcites →https://doi.org/10.1038/nrc1567openalex-snapshot
Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
inferredcites →https://doi.org/10.1056/nejmoa022457openalex-snapshot
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa0912614openalex-snapshot
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1002315openalex-snapshot
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1004095openalex-snapshot
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1609324openalex-snapshot
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1080/0284186x.2016.1201214openalex-snapshot
First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response – systematic review and meta-analysis
inferredcites →https://doi.org/10.1111/bjh.12618openalex-snapshot
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
inferredcites →https://doi.org/10.1111/ejh.12423openalex-snapshot
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study ( N ord CML 006)
inferredcites →https://doi.org/10.1136/bmj.d5928openalex-snapshot
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-1988openalex-snapshot
Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?
inferredcites →https://doi.org/10.1159/000454668openalex-snapshot
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
inferredcites →https://doi.org/10.1161/circulationaha.111.079921openalex-snapshot
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
inferredcites →https://doi.org/10.1182/blood-2008-09-180604openalex-snapshot
Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
inferredcites →https://doi.org/10.1182/blood-2008-12-191254openalex-snapshot
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
inferredcites →https://doi.org/10.1182/blood-2010-03-273979openalex-snapshot
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
inferredcites →https://doi.org/10.1182/blood-2012-02-410688openalex-snapshot
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
inferredcites →https://doi.org/10.1182/blood-2012-11-466037openalex-snapshot
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
inferredcites →https://doi.org/10.1182/blood-2013-03-490128openalex-snapshot
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
inferredcites →https://doi.org/10.1182/blood-2013-05-501569openalex-snapshot
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
inferredcites →https://doi.org/10.1182/blood-2013-06-510396openalex-snapshot
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
inferredcites →https://doi.org/10.1182/blood-2013-06-511592openalex-snapshot
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
inferredcites →https://doi.org/10.1182/blood-2013-10-532341openalex-snapshot
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
inferredcites →https://doi.org/10.1182/blood-2014-07-590315openalex-snapshot
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
inferredcites →https://doi.org/10.1182/blood-2014-09-594432openalex-snapshot
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
inferredcites →https://doi.org/10.1182/blood-2015-01-617993openalex-snapshot
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
inferredcites →https://doi.org/10.1182/blood-2016-01-694265openalex-snapshot
Moving treatment-free remission into mainstream clinical practice in CML
inferredcites →https://doi.org/10.1182/blood-2016-09-742205openalex-snapshot
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
inferredcites →https://doi.org/10.1182/blood.v124.21.517.517openalex-snapshot
Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML
inferredcites →https://doi.org/10.1186/1745-6215-8-16openalex-snapshot
Practical methods for incorporating summary time-to-event data into meta-analysis
inferredcites →https://doi.org/10.1200/jco.2009.25.3724openalex-snapshot
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
inferredcites →https://doi.org/10.1200/jco.2010.32.0598openalex-snapshot
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1200/jco.2011.38.7522openalex-snapshot
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
inferredcites →https://doi.org/10.1200/jco.2017.74.7162openalex-snapshot
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
inferredcites →https://doi.org/10.1200/jco.2017.75.4663openalex-snapshot
Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.3324/haematol.2015.139089openalex-snapshot
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis
inferredcites →https://doi.org/10.3324/haematol.2015.139337openalex-snapshot
Chronic myeloid leukemia: reminiscences and dreams
inferredcites →https://doi.org/10.7892/boris.78720openalex-snapshot
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3777190openalex-extracted
Relative Risk of Hepatotoxicity Associated With BCR-ABL Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.20165openalex-snapshot
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/s40199-019-00321-zopenalex-snapshot
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
inferred← citeshttps://doi.org/10.1055/s-0042-1756477openalex-snapshot
The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
inferred← citeshttps://doi.org/10.1080/03007995.2021.1896489openalex-snapshot
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1159/000501537openalex-snapshot
Systematic Review and Meta-Analysis of New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1182/bloodadvances.2019001329openalex-snapshot
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s12885-019-6039-9openalex-snapshot
Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis
inferred← citeshttps://doi.org/10.1186/s13045-024-01642-6openalex-snapshot
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
inferred← citeshttps://doi.org/10.33612/diss.568330158openalex-snapshot
Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis
inferred← citeshttps://doi.org/10.3389/fonc.2019.00372openalex-snapshot
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/cancers12051242openalex-snapshot
Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis
inferred← citeshttps://doi.org/10.3390/ph18040492openalex-snapshot
MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships
inferred← citeshttps://doi.org/10.51847/c9g2obovq3openalex-snapshot
Prolonged Follow-Up of ASC4MORE Demonstrates Sustained Efficacy and Tolerability of Asciminib Plus Imatinib in Patients with Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.70675/4518aa6dz9926z40c1z88aezd203c1f8f546openalex-snapshot
Données de "vraie vie" des inhibiteurs de protéines kinases dans la leucémie myéloïde chronique : profil d'utilisation à l'échelle française et impacts des interactions médicamenteuses des traitements concomitants
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.